Extramural Institutional Certification*

OMB Control Number: 0925-0670 Expiration Date: July 2019

For studies using data generated from cell lines created or clinical specimens collected before January 25, 2015

Date: [MM/DD/YYYY] Today's	Date Date		
Name of GPA: Find the na	me of your Genomic Program Adm	<mark>inistrator</mark>	
Genomic Program Administr	rator		
Select IC [, NIH, HHS Ty	pically this is "NCI", but it is referen	enced in JIT request	
9000 Rockville Pike		•	
Bethesda, MD 20892-7395			
Re: Institutional Certificatio	n of Your institu	tion name	[NAME OF INSTITUTION] to Accompany
Submission of the Dataset fr	om DF/HCC protocol number u	ınder which you are e	enrolling patients [ORIGINAL STUDY NAME] for
Enter grant title			[PROJECT TITLE FOR DATA TO BE SUBMITTED]
to an NIH-designated data re	pository.		
	e NIH-designated data reposito		with institutional approval from
	auto-populate, along with ap	opropriate instituti	onal approvals from
collaborating sites, as listed l	nere:		
[IF APPLICABLE ENTER COLLABORATING S	ITE NAMES HERE AND CLICK 'ADD TO LIST']	LIST OF COLLABORA	TING SITES
Add any protocol numbers or co	ollaborating institutions associated v	with your study (will	auto-populate Table on page 2)
Add to list >>		Clear list	
The Your Institution name	will auto-populate hereby as	ssures that submis	sion of data from the study entitled
Your grant title will auto			H-designated data repository meets
the following expectations, a	s defined in the NIH Genomic	Data Sharing Pol	icy:

- The data submission is consistent, as appropriate, with applicable national, tribal, and state laws and regulations as well as relevant institutional policies.
- Any limitations on the research use of the data, as expressed in the informed consent documents, are delineated in the table on page 3.
- The identities of research participants will not be disclosed to NIH-designated data repositories.
- An Institutional Review Board (IRB), and/or Privacy Board, and/or equivalent body, as applicable, has reviewed the investigator's proposal for data submission and assures that:
 - The protocol for the collection of genomic and phenotypic data is consistent with 45 CFR Part 46;²
 - Data submission and subsequent data sharing for research purposes are not inconsistent with the informed consent of study participants from whom the data were obtained;
 - Consideration was given to risks to individual participants and their families associated with data submitted to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results;
 - To the extent relevant and possible, consideration was given to risks to groups or populations associated with submitting data to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results; and
 - The investigator's plan for de-identifying datasets is consistent with the standards outlined in the NIH Genomic Data Sharing Policy (See section IV.C.1).

^{*} Certification must be provided for all sites contributing samples. If more than one site is contributing samples, the primary site may submit one Institutional Certification indicating that they are providing certification on behalf of all collaborating sites. Alternatively, each site providing samples may provide its own Institutional Certification.

The individual-level data are to	be made available through (check one)
⊙ controlled-access ³	DFCI and NCI strongly recommend selecting "controlled access".
O unrestricted access 4	Therefore, you must fill out Table on page 3
If unrestricted access is marked, completed.	, the data use limitations table on the following page(s) does not need to be
repositories through unrestricted a 'sensitivities' related to individua	results ⁵ (GSR) from most studies submitted to NIH-designated data access. However, data from data sets considered to have particular all privacy or potential for group harm (e.g., those with populations from ith rare or potentially stigmatizing traits) may be designated as "sensitive"
-	" should be checked below and a brief explanation for the sensitive GSR from any such data sets will only be available through controlled-
The genomic summary results ((GSR) from this study are only to be made available through

Explanation if controlled-access was selected for GSR.

Write justification here.

If you have a sensitive population (for example: Pediatric, HIV positive, or other

identifiable cohort) you may want to select "controlled-access"

Institutional Certification

necessary, create a customized DUL. DULs are developed based on the original informed consent of the participant(s). NIH expects the submitting institution(s) to select one of the three standard Data Use Limitations (DULs) for appropriate secondary use, or, if

Data Use Limitations

[ENTER CUSTOMIZED TEXT, IF APPLICABLE]		Other
Use of the data must be related to the specified disease.		Disease-specific [list disease] DS
Health/Medical/Biomedical HMB Use of the data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.	HMB	Health/Medical/Biomedical
GRU Use of the data is limited only by the terms of the Data Use Certification: these data will be added to the dbGaP Collection.	GRU	General Research Use

basis in the informed consent from the participants or in special knowledge of the preferences of the original study population. Additional modifiers to the standard DULs (e.g., Not-for-profit Use Only) can be indicated, if appropriate. Use of the modifiers should have a

Data Use Limitation Modifiers (Optional)

Genetic Studies Only GSO	Methods MDS	Not-for-profit Use Only NPU	Collaboration Required COL	Publication Required PUB	IRB Approval Required IRB
Use of the data is limited to genetic studies only.	Use of the data includes methods development research (e.g., development and testing of software or algorithms).	Use of the data is limited to not-for-profit organizations.	Requestor must provide a letter of collaboration with the primary study investigator(s).	Requestor agrees to make results of studies using the data available to the larger scientific community.	Requestor must provide documentation of local IRB approval.
needs to be dictated	determine which of these	It is highly recommended			

Using the tables above, please indicate in the table below the consent group(s) for each collaborating study site. Use one row per consent group.

Collaborating Site Name	Data Use Limitation	Data Use Limitation Modifiers (optional)
Eg: Cold Cohort Study	Health/Medical/Biomedical	IRB□ PUB□ COL□ NPU□ MDS□ GSO□
Eg: Cold Cohort Study	Disease Specific Research [Lung Cancer]	IRB□ PUB□ COL□ NPU図 MDS□ GSO□
Populated from page 1	Salact consent group like OHRS will determine this	IRB OHRS will determine this MDS GSO
	Select consent group title	IRB□ PUB□ COL□ NPU□ MDS GSO
	Select consent group title	IRB□ PUB□ COL□ NPU□ MDS GSO
	Select consent group title	IRB□ PUB□ COL□ NPU□ MDS GSO

Sincerely,					
Investigato	r:				
Name:	List the Principal Investigator's name	_Title:_	Principal Investigator		
Signature:	Validate and sign	Date:	Date signed by PI		
PIs signs this once returned by OHRS Institutional Signing Official:6 By signing below, I certify on behalf of that, in addition to myself, an IRB or Privacy Board or equivalent body, and other relevant senior-level institutional staff (e.g., Dean, Vice President/Provost for Research, Chief Science Officer) have reviewed the requirements in this certification and agree that the submission meets them.					
Name:	Institutional Signing Official (ISO)	_Title:_			
Signature:		_Date:_			

References

- Original Study Name should reflect the name of the original IRB-approved study (e.g., cohort or case-control study, clinical trial) under which participants provided informed consent and biospecimens were collected (e.g., Nurses' Health Study, Framingham Heart Study).
- 2. 45 CFR Part 46. Protection of Human Subjects. See https://www.gpo.gov/fdsys/pkg/ CFR-2013-title45-vol1/xml/CFR-2013-title45-vol1-part46.xml.
- Data made available for secondary research only after investigators have obtained approval from NIH to use the requested data for a particular project.
- 4. Data made publicly available to anyone.
- 5. Genomic summary results are results from primary analyses of genomic research that convey information relevant to genomic associations with traits or diseases across datasets rather than data specific to any one individual research participant (e.g., genotype counts and frequencies; allele counts and frequencies; effect size estimates and standard errors; likelihoods; and p-values).
- 6. Under the NIH Genomic Data Sharing Policy, an Institutional Signing Official is generally a senior official at an institution who is credentialed through the NIH eRA Common system and is authorized to enter the institution into a legally binding contract and sign on behalf of an investigator who has submitted data or a data access request to NIH.